Development of a more efficient hepatitis B virus vaccine by targeting hepatitis B virus preS to dendritic cells |
| |
| Affiliation: | 1. State Key Laboratory of Virology and College of Life Sciences, Wuhan University, Wuhan 430072, China;2. Clinical Research Center, Wuhan Children''s Hospital, Wuhan 430016, China;1. Hepatitis Group, National Institute of Virology, Pune, 130/1, Sus Road, Pashan, Pune 411021, Maharashtra, India;2. Interactive Research School in Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Katraj-Dhankawadi, Pune 411043, Maharashtra, India;1. Thailand Ministry of Public Health–U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand;2. Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA;3. Thai Red Cross Society AIDS Research Center, Bangkok, Thailand;1. Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), PO Box 1, Bilthoven 3720 BA, The Netherlands;2. Department of Toxicogenomics, Maastricht University Medical Centre, Universiteitssingel 50, Maastricht 6229 ER, The Netherlands;3. Centre for Infectious Disease Control Netherlands, National Institute for Public Health and the Environment (RIVM), Bilthoven 3720 BA, The Netherlands;1. Research Institute of Influenza, Russian Federation Ministry of Health, St. Petersburg, Russia;2. Centre “Bioengineering”, Russian Academy of Science, Moscow, Russia;1. Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Shandong Agricultural University, Taian 271018, China;2. Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Taian 271018, China;3. Shandong Provincial Engineering Technology Research Center of Animal Disease Control and Prevention, Taian 271018, China;1. Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda;2. Global Health Institute, University of Antwerp, Belgium;3. Clinical Epidemiology Unit, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda;4. Department of Paediatrics, Gulu University School of Medicine, Gulu, Uganda;5. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda |
| |
| Abstract: | BackgroundConventional hepatitis B virus (HBV) vaccines fail to induce protective antibody titers in 5–10% of immune-competent vaccinees. Therefore, there remains an urgent need to develop a safe and effective HBV vaccine.MethodsIn this study, we developed an effective and economical method for producing the HBV vaccine by using the high binding capacity of biotin–streptavidin. The preS antigen of HBV was fused with the core streptavidin (cSA) moiety (preS-cSA) and highly expressed in Escherichia coli. We investigated whether the preS-cSA protein could target dendritic cells (DCs) by binding a biotinylated antibody against the DC receptor CD205 (biotin-αCD205). Moreover, we evaluated the preS-cSA/biotin-αCD205 complex as a candidate vaccine by detecting the humoral and cellular immune responses elicited by this vaccine.ResultsOur data show that the preS-cSA/biotin-αCD205 complex targeted DCs and induced high anti-HBV antibody titers of IgG2a, IgG1, and IgG in vivo. Furthermore, vaccination with the preS-cSA/biotin-αCD205 complex prevented HBV infection in female mice. More interestingly, this novel vaccine exerted a therapeutic role in mice with HBV infection.ConclusionsTaken together, our results reveal that the preS-cSA/biotin-αCD205 vaccine induces effective immunological protection against HBV, and is a promising candidate for preventing HBV infections. |
| |
| Keywords: | Vaccine Hepatitis B virus preS Dendritic cells |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
